Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Chk1 inhibitor SCH 900776 enhances the antitumor activity of MLN4924 on pancreatic cancer
Li, Jian-ang, Rong, Yefei , Kuang, Tiantao , Wang, Dansong , Xu, Xuefeng , Yuan, Jian , Luo, Kuntian, Qin, Bo , Nowsheen, Somaira , Lou, Wenhui , Yuan, Jian , Nowsheen, Somaira , Song, Chao , Lou, Zhenkun , Lou, Wenhui

Mayo Clinic

Cell Cycle | November 21, 2017 | Volume: 17 | Issue: 2 | Pages: 191-199

10.1080/15384101.2017.1405194 | PMID 29157102 Get It

Considerations for automated machine learning in clinical metabolic profiling: Altered homocysteine plasma concentration associated with metformin exposure
Orlenko, Alena , Orzechowski, Patryk , Olson, Randal S. , Cairns, Junmei , Weinshilboum, Richard M. , Wang, Liewei , Breitenstein, Matthew K. , Moore, Jason H. , Caraballo, Pedro J. , Weinshilboum, Richard M.

Mayo Clinic

Biocomputing 2018 | November 17, 2017 | Volume: No volume available | Issue: No issue available | Pages: 460-471

10.1142/9789813235533_0042 Get It

Leveraging word embeddings and medical entity extraction for biomedical dataset retrieval using unstructured texts
Wang, Yanshan , Komandur-Elayavilli, Ravikumar, Rastegar-Mojarad, Majid, Rastegar-Mojarad, Majid , Liu, Hongfang , Wang, Yanshan

Mayo Clinic

Database | November 16, 2017 | Volume: 2017 | Issue: No issue available | Pages: No page available

10.1093/database/bax091 | PMID 31725862 Get It

AbstractThe recent movement towards open data in the biomedical domain has generated a large number of datasets that are publicly accessible. The Big Data to Knowledge data indexing project, biomedical and healthCAre Data Discovery Index Ecosystem (bioCADDIE), has gathered these datasets in a one-stop portal aiming at facilitating their reuse for accelerating scientific advances. However, as the number of biomedical datasets stored and indexed increases, it becomes more and more challenging to retrieve the relevant datasets according to researchers’ queries. In this article, we propose an information retrieval (IR) system to tackle this problem and implement it for the bioCADDIE Dataset Retrieval Challenge. The system leverages the unstructured texts of each dataset including the title and description for the dataset, and utilizes a state-of-the-art IR model, medical named entity extraction techniques, query expansion with deep learning-based word embeddings and a re-ranking strategy to enhance the retrieval performance. In empirical experiments, we compared the proposed system with 11 baseline systems using the bioCADDIE Dataset Retrieval Challenge datasets. The experimental results show that the proposed system outperforms other systems in terms of inference Average Precision and inference normalized Discounted Cumulative Gain, implying that the proposed system is a viable option for biomedical dataset retrieval.Database URL: https://github.com/yanshanwang/biocaddie2016mayodata
Clinical Impact of Diabetes Mellitus on Outcomes After Transcatheter Aortic Valve Replacement
Abramowitz, Yigal, Vemulapalli, Sreekanth , Chakravarty, Tarun , Li, Zhuokai , Holmes, David R. , Wang, Alice , Cheng, Wen , Forrester, James S. , Smalling, Richard W. , Thourani, Vinod H. , Mack, Michael J. , Leon, Martin B. , Makkar, Raj , Douglas, Pamela S. , Matsouaka, Roland A, Smalling, Richard, Thourani, Vinod, Mack, Michael, Leon, Martin, Makkar, Raj R., Douglas, Pamela S , Kapadia, Samir , Matsouaka, Roland

Mayo Clinic

Circulation: Cardiovascular Interventions | November 14, 2017 | Volume: 10 | Issue: 11 | Pages: No page available

10.1161/circinterventions.117.005417 | PMID 29138245 Get It

Background— Diabetes mellitus (DM) adversely affects morbidity and mortality for cardiovascular diseases and procedures. Data evaluating the outcomes of transcatheter aortic valve replacement (TAVR) in diabetic patients are limited by small sample size and contradictory results. We aimed to establish the magnitude of risk and the incremental influence of insulin dependency by examining short- and long-term adverse outcomes according to DM status and therapy in the world’s largest TAVR registry. Methods and Results— We analyzed data from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. In-hospital mortality, 30-day mortality, and 1-year mortality after TAVR in patients with and without DM were evaluated using multivariate modeling. Among 47 643 patients treated with TAVR from November 2011 through September 2015 at 394 US hospitals, there were 17 849 (37.5%) patients with DM. Overall, 6600 of the diabetic patients were insulin treated (IT). Thirty-day mortality was 5.0% in patients with DM (6.1% in IT DM and 4.4% in non-IT DM; P <0.001) versus 5.9% in patients without DM ( P <0.001). Overall, 1-year mortality was 21.8% in patients with DM (24.8% in IT DM and 20.1% in non-IT DM; P <0.001) versus 21.2% in patients without DM ( P =0.274). In a multivariable model, DM was associated with increased 1-year mortality (hazard ratio, 1.30; 95% confidence interval, 1.13–1.49; P <0.001). Subgroup multivariable analysis showed stronger mortality association in IT diabetics (hazard ratio, 1.57; 95% confidence interval, 1.28–1.91; P <0.001) than in non-IT diabetics (hazard ratio, 1.17; 95% confidence interval, 1.00–1.38; P =0.052). Conclusions— Our data establish the magnitude of short- and long-term risk conferred by DM and the incremental risk conferred by insulin dependency in the performance of TAVR. Clinical Trial Registration— URL: https://www.clinicaltrials.gov . Unique identifier: NCT01737528.
Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma
García, Héctor Alexander Velásquez , Spinelli, John J., Gaffney, Patrick M. , Smedby, Karin E. , Wang, Sophia , Adami, Hans‐Olov , Angelucci, Emanuele , Ansell, Stephen M. , Asmann, Yan W. , Becker, Nikolaus, Benavente, Yolanda , Berndt, Sonja I. , Bertrand, Kimberly A. , Birmann, Brenda M. , Boeing, Heiner , Bracci, Paige M. , Brennan, Paul , Brooks‐Wilson, Angela , Clavel, Jacqueline , Conde, Lucía , Cotenbader, Karen H, Cox, David G. , Crouch, Simon , Roos, Anneclaire J. De , Sanjosé, Sílvia de , Lollo, Simonetta Di, Diver, W. Ryan , Foretová, Lenka , Ghesquières, Hervé , Glimelius, Bengt , Haïoun, Corinne , Hartge, Patricia, Hjalgrim, Henrik , Holford, Theodore R. , Holly, Elizabeth A., Jackson, Rebecca D. , Kaaks, Rudolph, Kane, Eleanor , Klein, Robert J. , Kraft, Peter , Kricker, Anne , Lan, Qing , Lawrence, Charles , Liebow, Mark , Lightfoot, Tracy, Link, Brian K. , Maynadié, Marc, McKay, James , Melbye, Mads , Molina, Thierry Jo , Monnereau, Alain , Morton, Lindsay M. , Nieters, Alexandra, Novak, Anne J. , Offit, Kenneth , Purdue, Mark P. , Rais, Marco, Riby, Jacques, Roman, Eve , Rothman, Nathaniel , Salles, Gilles , Severi, Gianluca , Severson, Richard K., Skibola, Christine F., Smith, Martyn T. , Southey, Melissa C. , Staines, Anthony , Thompson, Carrie A. , Tilly, Hervé , Tinker, Lesley F. , Tjønneland, Anne , Turner, Jennifer , Vajdic, Claire M. , Vermeulen, Roel , Vijai, Joseph , Vineis, Paolo , Virtamo, Jarmo, Wang, Zhaoming , Weinstein, Stephanie J. , Zheng, Tongzhang, Zucca, Mariagrazia, Clarke, Ann E. , Smith, Alexandra , Bertrand, Kimberly A , Turner, Jennifer , Link, Brian K , Joseph, Vijai , Southey, Melissa C , Brooks-Wilson, Angela R , Vajdic, Claire M , Kane, Eleanor , Tjønneland, Anne , Wang, Zhaoming , Severi, Gianluca , Kraft, Peter , Morton, Lindsay M , De Roos, Anneclaire J , Salles, Gilles A , Wang, Sophia S , Birmann, Brenda M , Roman, Eve , Clavel, Jacqueline , Smith, Alexandra , Bernatsky, Sasha , Ramsey‐Goldman, Rosalind , Albanes, Demetrius , Boffetta, Paolo , Cerhan, James R. , Chanock, Stephen Jacob , Cozen, Wendy , Doǧan, Ahmet , Giles, Graham G. , Habermann, Thomas M. , Kelly, Rachel S. , North, Kari E. , Slager, Susan L. , Smith, Alex, Teras, Lauren R. , Witzig, Thomas E. , Zelenetz, Andrew D. , Zeleniuch‐Jacquotte, Anne , Zhang, Yawei , Angelucci, Emanuele , Klein, Robert

Mayo Clinic

Lupus Science & Medicine | November 13, 2017 | Volume: 4 | Issue: 1 | Pages: e000187

10.1136/lupus-2016-000187 | PMID 29214033 Get It

Objective Determinants of the increased risk of diffuse large B-cell lymphoma (DLBCL) in SLE are unclear. Using data from a recent lymphoma genome-wide association study (GWAS), we assessed whether certain lupus-related single nucleotide polymorphisms (SNPs) were also associated with DLBCL. Methods GWAS data on European Caucasians from the International Lymphoma Epidemiology Consortium (InterLymph) provided a total of 3857 DLBCL cases and 7666 general-population controls. Data were pooled in a random-effects meta-analysis. Results Among the 28 SLE-related SNPs investigated, the two most convincingly associated with risk of DLBCL included the CD40 SLE risk allele rs4810485 on chromosome 20q13 (OR per risk allele=1.09, 95% CI 1.02 to 1.16, p=0.0134), and the HLA SLE risk allele rs1270942 on chromosome 6p21.33 (OR per risk allele=1.17, 95% CI 1.01 to 1.36, p=0.0362). Of additional possible interest were rs2205960 and rs12537284. The rs2205960 SNP, related to a cytokine of the tumour necrosis factor superfamily TNFSF4, was associated with an OR per risk allele of 1.07, 95% CI 1.00 to 1.16, p=0.0549. The OR for the rs12537284 (chromosome 7q32, IRF5 gene) risk allele was 1.08, 95% CI 0.99 to 1.18, p=0.0765. Conclusions These data suggest several plausible genetic links between DLBCL and SLE.
Comprehensive Profiling of lincRNAs in Lung Adenocarcinoma of Never Smokers Reveals Their Roles in Cancer Development and Prognosis
Wang, Zheng , Nair, Asha, Zhang, Xiaoju , Sun, Zhifu , Sun, Zhifu , Li, Ying , Song, Wei , Yang, Ping

Mayo Clinic

Genes | November 13, 2017 | Volume: 8 | Issue: 11 | Pages: 321

10.3390/genes8110321 | PMID 29137177 Get It

Long intergenic non-coding RNA (lincRNA) is a family of gene transcripts, the functions of which are largely unknown. Although cigarette smoking is the main cause for lung cancer, lung cancer in non-smokers is a separate entity and its underlying cause is little known. Growing evidence suggests lincRNAs play a significant role in cancer development and progression; however, such data is lacking for lung cancer in non-smokers, or those who have never smoked. This study conducted comprehensive profiling of lincRNAs from RNA sequencing (RNA-seq) data of non-smoker patients with lung adenocarcinoma. Both known and novel lincRNAs distinctly segregated tumors from normal tissues. Approximately one third of lincRNAs were differentially expressed between tumors and normal samples and most of them were coordinated with their putative protein gene targets. More importantly, lincRNAs defined two clusters of tumors that were associated with tumor aggressiveness and patient survival. We identified a subset of lincRNAs that were differentially expressed and also associated with patient survival. Very high concordance (R2 = 0.9) was observed for the differentially expressed lincRNAs in the Cancer Genome Atlas (TCGA) validation set of 85 transcriptomes and the lincRNAs associated with survival from the discovery set were similarly predictive in the validation set. These lincRNAs warrant further investigation as potential diagnostic and prognostic markers.
Fingolimod Protects Against Ischemic White Matter Damage by Modulating Microglia Toward M2 Polarization via STAT3 Pathway
Qin, Chuan , Fan, Wen-Hui, Shang, Ke , Murugan, Madhuvika , Wu, Long‐Jun , Wang, Wei , Tian, Dai‐Shi , Wu, Long-Jun , Tian, Dai-Shi , Liu, Qian

Mayo Clinic

Stroke | November 7, 2017 | Volume: 48 | Issue: 12 | Pages: 3336-3346

10.1161/strokeaha.117.018505 | PMID 29114096 Get It

Background and Purpose— White matter (WM) ischemic injury, a major neuropathological feature of cerebral small vessel diseases, is an important cause of vascular cognitive impairment in later life. The pathogenesis of demyelination after WM ischemic damage are often accompanied by microglial activation. Fingolimod (FTY720) was approved for the treatment of multiple sclerosis for its immunosuppression property. In this study, we evaluated the neuroprotective potential of FTY720 in a WM ischemia model. Methods— Chronic WM ischemic injury model was induced by bilateral carotid artery stenosis. Cognitive function, WM integrity, microglial activation, and potential pathway involved in microglial polarization were assessed after bilateral carotid artery stenosis. Results— Disruption of WM integrity was characterized by demyelination in the corpus callosum and disorganization of Ranvier nodes using Luxol fast blue staining, immunofluorescence staining, and electron microscopy. In addition, radial maze test demonstrated that working memory performance was decreased at 1-month post–bilateral carotid artery stenosis–induced injury. Interestingly, FTY720 could reduce cognitive decline and ameliorate the disruption of WM integrity. Mechanistically, cerebral hypoperfusion induced microglial activation, production of associated proinflammatory cytokines, and priming of microglial polarization toward the M1 phenotype, whereas FTY720 attenuated microglia-mediated neuroinflammation after WM ischemia and promoted oligodendrocytogenesis by shifting microglia toward M2 polarization. FTY720’s effect on microglial M2 polarization was largely suppressed by selective signal transducer and activator of transcription 3 (STAT3) blockade in vitro, revealing that FTY720-enabled shift of microglia from M1 to M2 polarization state was possibly mediated by STAT3 signaling. Conclusions— Our study suggested that FTY720 might be a potential therapeutic drug targeting brain inflammation by skewing microglia toward M2 polarization after chronic cerebral hypoperfusion.
Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years
Duma, Narjust , Aguilera, Jesus Vera, Vélez, Miguel González , Leventakos, Konstantinos , Mansfield, Aaron S. , Adjei, Alex A. , Vera Aguilera, Jesus, Gonzalez Velez, Miguel, Hubbard, Joleen M. , Mansfield, Aaron S , Paludo, Jonas , Haddox, Candace L. , Wang, Yucai , Go, Ronald S.

Mayo Clinic

Journal of Oncology Practice | November 3, 2017 | Volume: 14 | Issue: 1 | Pages: e1-e10

10.1200/jop.2017.025288 | PMID 29099678 Get It

Purpose: Many cancer clinical trials lack appropriate representation of specific patient populations, limiting their generalizability. Therefore, we determined the representation of ethnic minorities and women in cancer clinical trials. Methods: Enrollment data from all therapeutic trials reported as completed in ClinicalTrials.gov from 2003 to 2016 were analyzed. We calculated enrollment fractions (EFs) for each group, defined as the number of enrollees divided by the 2013 Surveillance, Epidemiology, and End Results (SEER) database cancer prevalence. Results: Of 1,012 clinical trials, 310 (31%) reported ethnicity with a total of 55,689 enrollees. Participation varied significantly across ethnic groups. Non-Hispanic whites were more likely to be enrolled in clinical trials (EF, 1.2%) than African Americans (EF, 0.7%; P < .001) and Hispanics (EF, 0.4%; P < .001). A decrease in African American (6% v 9.2%) and Hispanic (2.6% v 3.1%) enrollment was observed when compared with historical data from 1996 to 2002. Younger patients (age younger than 65 years) were more likely to be enrolled in clinical trials than the elderly (64% v 36%; P < .001). Low recruitment of female patients was observed in clinical trials for melanoma (35%), lung cancer (39%), and pancreatic cancer (40%). Conclusion: We observed a decrease in recruitment of minorities over the past 14 years compared with historical data. African Americans, Hispanics, and women were less likely to be enrolled in cancer clinical trials. Future trials should take extra measures to recruit participants that adequately represent the US cancer population.
Conserved brain myelination networks are altered in Alzheimer's and other neurodegenerative diseases
Allen, Mariet , Wang, Xue , Burgess, Jeremy D. , Serie, Daniel, Younkin, Curtis, Nguyen, Thuy , Malphrus, Kimberly G., Lincoln, Sarah, Carrasquillo, Minerva M. , Ho, Charlotte C.G. , Chakrabarty, Paramita , Strickland, Samantha L. , Murray, Melissa E. , Geschwind, Daniel H. , Seyfried, Nicholas T. , Dammer, Eric B. , Levey, Allan I. , Golde, Todd E. , Funk, Cory C. , Li, Hongdong , Price, Nathan D. , Petersen, Ronald C. , Graff‐Radford, Neill R. , Younkin, Steven G. , Crook, Julia, Asmann, Yan W. , Ertekin‐Taner, Nilüfer , Watzlawik, Jens, Serie, Daniel J, Younkin, Curtis S, Ho, Charlotte, Crook, Julia R, Price, Nathan D , Murray, Melissa E , Watzlawik, Jens O. , Carrasquillo, Minerva M. , Swarup, Vivek , Lah, James J. , Li, Hongdong, Dickson, Dennis W. , Dammer, Eric B , Levey, Allan I

Mayo Clinic

Alzheimer's & Dementia | October 31, 2017 | Volume: 14 | Issue: 3 | Pages: 352-366

10.1016/j.jalz.2017.09.012 | PMID 29107053 Get It

Abstract Introduction Comparative transcriptome analyses in Alzheimer's disease (AD) and other neurodegenerative proteinopathies can uncover both shared and distinct disease pathways. Methods We analyzed 940 brain transcriptomes including patients with AD, progressive supranuclear palsy (PSP; a primary tauopathy), and control subjects. Results We identified transcriptional coexpression networks implicated in myelination, which were lower in PSP temporal cortex (TCX) compared with AD. Some of these associations were retained even after adjustments for brain cell population changes. These TCX myelination network structures were preserved in cerebellum but they were not differentially expressed in cerebellum between AD and PSP. Myelination networks were downregulated in both AD and PSP, when compared with control TCX samples. Discussion Downregulation of myelination networks may underlie both PSP and AD pathophysiology, but may be more pronounced in PSP. These data also highlight conservation of transcriptional networks across brain regions and the influence of cell type changes on these networks.
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer
Renfro, Lindsay A. , Hurwitz, Herbert I. , Safran, Howard , Guarino, Michael J., Kim, George P., Hecht, J. Randolph, Weil, Susan C., Heyburn, John, Schweizer, Charles, O’Shannessy, Daniel J., Díaz, Luis A. , Diaz, Luis A , Grothey, Axel , Strosberg, Jonathan , Marshall, John L , Wang, Wenquan

Mayo Clinic

Clinical Cancer Research | October 30, 2017 | Volume: 24 | Issue: 2 | Pages: 316-325

10.1158/1078-0432.ccr-17-1558 | PMID 29084918 Get It

Abstract Purpose: The purpose of this study was to evaluate the safety and efficacy of ontuxizumab (MORAb-004), a monoclonal antibody that interferes with endosialin (tumor endothelial marker-1) function, in patients with chemorefractory metastatic colorectal cancer and to identify a responsive patient population based on biomarkers. Experimental Design: This was a randomized, double-blind, placebo-controlled, phase II study. Patients were randomly assigned in a 2:1 ratio to receive weekly intravenous ontuxizumab (8 mg/kg) or placebo plus best supportive care until progression or unacceptable toxicity. Tissue and blood biomarkers were evaluated for their ability to identify a patient population that was responsive to ontuxizumab. Results: A total of 126 patients were enrolled. No significant difference between the ontuxizumab and placebo groups was evident for the primary endpoint of progression-free survival (PFS), with a median PFS of 8.1 weeks in each group (HR, 1.13; 95% confidence interval, 0.76–1.67; P = 0.53). There were no significant differences between groups for overall survival (OS) or overall response rate (ORR). The most common treatment-emergent adverse events (TEAEs) in the ontuxizumab group (vs. the placebo group, respectively) were fatigue (53.7% vs. 47.5%), nausea (39.0% vs. 35.0%), decreased appetite (34.1% vs. 27.5%), and constipation (28.0% vs. 32.5%). The most common grade 3/4 TEAE in the ontuxizumab group versus placebo was back pain (11.0% vs. 0%). No single biomarker clearly identified patients responsive to ontuxizumab. Conclusions: No benefit with ontuxizumab monotherapy compared with placebo for clinical response parameters of PFS, OS, or ORR was demonstrated. Ontuxizumab was well tolerated. Clin Cancer Res; 24(2); 316–25. ©2017 AACR.